Johnny Ludvigsson

Diamyd Medical is a Swedish clinical-stage biopharmaceutical company specializing in precision medicine for Type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA). The company's lead product, Diamyd®, is an antigen-specific immunotherapy (vaccine) designed to preserve endogenous insulin production in patients with the HLA DR3-DQ2 genetic profile. Founded on the pioneering research of Professor Johnny Ludvigsson, who serves as a key scientific advisor and principal investigator, the company is currently conducting the pivotal Phase 3 DIAGNODE-3 trial. Diamyd Medical also develops Remygen®, an oral GABA-based therapeutic aimed at regenerating beta cells and improving metabolic control. The company operates its own specialized manufacturing facility in Umeå, Sweden, for the production of recombinant GAD65 protein. Diamyd Medical is publicly traded on the Nasdaq First North Growth Market.